Table 3.
Toxicity and grade | 6-week schedule |
5-week schedule |
Total |
||
---|---|---|---|---|---|
Group 1 (n = 35) | Group 2 (n = 47) | Group 1 (n = 12) | Group 2 (n = 24) | (n = 118†) | |
Pneumonitis | |||||
1 | 13 (37%) | 11 (23%) | 1 (8%) | 4 (17%) | 29 (25%) |
2 | 10 (29%) | 12 (26%) | 4 (33%) | 4 (17%) | 30 (25%) |
3 | 2 (6%) | 1 (2%) | 0 | 1 (4%) | 4 (3%) |
4 | 0 | 0 | 0 | 0 | 0 |
5 | 0 | 0 | 0 | 0 | 0 |
Esophagitis | |||||
1 | 1 (3%) | 4 (9%) | 0 | 0 | 5 (4%) |
2 | 30 (86%) | 33 (70%) | 11 (92%) | 22 (92%) | 96 (81%) |
3 | 2 (6%) | 3 (6%) | 1 (8%) | 1 (4%) | 7 (6%) |
4 | 0 | 0 | 0 | 0 | 0 |
5 | 0 | 0 | 0 | 0 | 0 |
Any adverse event | |||||
1 | 0 | 0 | 0 | 0 | 0 |
2 | 8 (23%) | 10 (21%) | 5 (42%) | 6 (25%) | 29 (25%) |
3 | 21 (60%) | 26 (55%) | 7 (58%) | 18 (75%) | 72 (61%) |
4 | 4 (11%) | 9 (19%) | 0 | 0 | 13 (11%) |
5 | 2 (6%) | 2 (4%) | 0 | 0 | 4 (3%) |
Any adverse event at least possibly related to radiation therapy | |||||
1 | 0 | 2 (4%) | 0 | 0 | 2 (2%) |
2 | 17 (49%) | 19 (40%) | 8 (67%) | 17 (71%) | 61 (52%) |
3 | 13 (37%) | 20 (43%) | 4 (33%) | 7 (29%) | 44 (37%) |
4 | 3 (9%) | 6 (13%) | 0 | 0 | 9 (8%) |
5 | 2 (6%) | 0 | 0 | 0 | 2 (2%) |
The table summarizes the highest grades of pneumonitis, esophagitis, and adverse events experienced by each patient.
Of 120 patients recruited, 118 began treatment.